33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Analyze analyst forecasts for the company and compare them with competitors.
1.53B
The estimated revenue has increased from the previous period.
-973.18M
The estimated EBITDA has decreased from the previous period.
0.28
The estimated EPS has increased from the previous period.
149.77M
The estimated net income has increased from the previous period.
-1.09B
The estimated EBIT has decreased from the previous period.
1.72B
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
2.61B
Revenue has increased from the previous period.
66.85%
Revenue growth rate is unchanged from the previous period.
-1.66B
EBITDA has decreased from the previous period.
-63.74%
EBITDA margin is unchanged from the previous period.
-1.87B
EBIT has decreased from the previous period.
-71.70%
EBIT margin is unchanged from the previous period.
315.80M
Depreciation has increased from the previous period.
2.39B
Total cash has increased from the previous period.
91.68%
Cash percentage is unchanged from the previous period.
525.47M
Receivables have increased from the previous period.
20.14%
Receivables percentage is unchanged from the previous period.
185.59M
Inventories have increased from the previous period.
7.11%
Inventory percentage is unchanged from the previous period.
228.75M
Accounts payable has increased from the previous period.
8.77%
Payables percentage is unchanged from the previous period.
-253.89M
Capital expenditure has increased from the previous period.
-9.73%
CapEx percentage is unchanged from the previous period.
11.55%
WACC is unchanged from the previous period.
11.58%
Cost of equity is unchanged from the previous period.
4.40%
Cost of debt is unchanged from the previous period.
1.52
Beta is unchanged from the previous period.
534.88M
Diluted shares outstanding is unchanged from the previous period.
99.49M
Total debt is unchanged from the previous period.
23.34B
Total equity is unchanged from the previous period.
23.44B
Total capital is unchanged from the previous period.
0.42%
Debt weighting is unchanged from the previous period.
99.58%
Equity weighting is unchanged from the previous period.
-1.87B
EBIAT has decreased from the previous period.
-2.00B
UFCF has decreased from the previous period.
2.00%
Long-term growth rate is unchanged from the previous period.
-99.35B
Terminal value is unchanged from the previous period.
-71.64B
Enterprise value is unchanged from the previous period.
-36.05M
Net debt is unchanged from the previous period.
-71.60B
Equity value is unchanged from the previous period.
-133.86
Equity value per share is unchanged from the previous period.
View analysts' price targets and recommendations, and compare them with competitors.
$49.00
Lower upside than BRZE's upside of 77.52%.
Buy
Equal to BRZE's analyst recommendation of Buy.
